CN101142225B - 具有抗炎活性的大环内酯 - Google Patents

具有抗炎活性的大环内酯 Download PDF

Info

Publication number
CN101142225B
CN101142225B CN2006800081835A CN200680008183A CN101142225B CN 101142225 B CN101142225 B CN 101142225B CN 2006800081835 A CN2006800081835 A CN 2006800081835A CN 200680008183 A CN200680008183 A CN 200680008183A CN 101142225 B CN101142225 B CN 101142225B
Authority
CN
China
Prior art keywords
compound
group
alkyl
formula
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800081835A
Other languages
English (en)
Chinese (zh)
Other versions
CN101142225A (zh
Inventor
奥格珍·卡利克
马丁纳·博斯纳
尼古拉·马杰诺维克
杜布拉夫科·杰利克
苏利曼·阿利霍齐克
范杰·维拉
佐里卡·马鲁西克-伊斯图克
维斯纳·伊拉科维克
贝里斯拉夫·博斯恩杰克
博斯卡·赫瓦西克
玛丽杰·托马斯科维克
维斯纳·穆尼克
瓦妮莎·艾维蒂克
安滕·赫坦克
戈兰·克拉戈尔
玛丽杰·勒杰克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
GlaxoSmithKline Istrazivacki Centar Zagreb doo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, GlaxoSmithKline Istrazivacki Centar Zagreb doo filed Critical Glaxo Group Ltd
Publication of CN101142225A publication Critical patent/CN101142225A/zh
Application granted granted Critical
Publication of CN101142225B publication Critical patent/CN101142225B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2006800081835A 2005-01-13 2006-01-13 具有抗炎活性的大环内酯 Expired - Fee Related CN101142225B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US64384105P 2005-01-13 2005-01-13
US60/643,841 2005-01-13
US71582805P 2005-09-09 2005-09-09
US60/715,828 2005-09-09
PCT/IB2006/001238 WO2006087644A2 (en) 2005-01-13 2006-01-13 Macrolides with anti-inflammatory activity

Publications (2)

Publication Number Publication Date
CN101142225A CN101142225A (zh) 2008-03-12
CN101142225B true CN101142225B (zh) 2011-09-07

Family

ID=36916830

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800081835A Expired - Fee Related CN101142225B (zh) 2005-01-13 2006-01-13 具有抗炎活性的大环内酯

Country Status (18)

Country Link
US (2) US8080529B2 (OSRAM)
EP (1) EP1851236B1 (OSRAM)
JP (1) JP5036558B2 (OSRAM)
KR (1) KR20070105993A (OSRAM)
CN (1) CN101142225B (OSRAM)
AT (1) ATE476438T1 (OSRAM)
AU (1) AU2006215315B2 (OSRAM)
CA (1) CA2594820A1 (OSRAM)
CY (1) CY1110866T1 (OSRAM)
DE (1) DE602006015919D1 (OSRAM)
DK (1) DK1851236T3 (OSRAM)
HR (1) HRP20100549T1 (OSRAM)
IL (1) IL184438A (OSRAM)
NO (1) NO20074162L (OSRAM)
PL (1) PL1851236T3 (OSRAM)
PT (1) PT1851236E (OSRAM)
RS (1) RS51479B (OSRAM)
WO (1) WO2006087644A2 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009130189A1 (en) * 2008-04-23 2009-10-29 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. 2'-o,3'-n-bridged macrolides
CN101423539B (zh) * 2008-12-09 2011-04-27 山东大学 4″,11-二氨基甲酸酯阿奇霉素衍生物、制备方法及其药物组合物
CN102378763A (zh) 2009-01-30 2012-03-14 葛兰素集团有限公司 消炎的大环内酯
ES2582794T3 (es) 2009-08-13 2016-09-15 Basilea Pharmaceutica Ag Nuevos macrólidos y su uso
WO2011131749A1 (en) 2010-04-23 2011-10-27 Glaxo Group Limited New 14 and 15 membered macrolides for the treatment of neutrophil dominated inflammatory diseases
JP6437523B2 (ja) 2013-04-04 2018-12-12 プレジデント アンド フェローズ オブ ハーバード カレッジ マクロライドならびにそれらの調製および使用の方法
CA2908620A1 (en) 2013-04-10 2014-10-16 Probiotic Pharmaceuticals Aps Azithromycin antimicrobial derivatives with non-antibiotic pharmaceutical effect
US10633407B2 (en) 2014-10-08 2020-04-28 President And Fellows Of Harvard College 14-membered ketolides and methods of their preparation and use
EP3273969A4 (en) 2015-03-25 2018-11-21 President and Fellows of Harvard College Macrolides with modified desosamine sugars and uses thereof
GB201520419D0 (en) 2015-11-19 2016-01-06 Epi Endo Pharmaceuticals Ehf Compounds
EP4118092B1 (en) * 2020-03-12 2025-07-16 Zoetis Services LLC Immunomodulating o-het-aryl azalides
WO2022128054A1 (en) 2020-12-14 2022-06-23 Symrise Ag Medicament for fighting inflammatory conditions of human skin (iv)
CN114858953B (zh) * 2022-05-20 2023-11-21 大连工业大学 一种动物源食品中红霉素及降解产物的检测试剂盒及检测方法
GB202404587D0 (en) 2024-03-28 2024-05-15 Epiendo Pharmaceuticals Ehf Chemical forms

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0895999A1 (en) * 1997-08-06 1999-02-10 Pfizer Products Inc. C-4" substituted macrolide antibiotics

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126344A2 (en) * 1983-05-20 1984-11-28 Abbott Laboratories Tripeptide esters of therapeutic agents
SI9011409A (en) * 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
HRP980189B1 (en) 1998-04-06 2004-04-30 Pliva Pharm & Chem Works Novel 15-membered lactams ketolides
AU2003255851B2 (en) * 2002-07-08 2009-07-23 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. New compounds, compositions and methods for treatment of inflammatory diseases and conditions
GB0310986D0 (en) * 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
WO2006077501A2 (en) 2005-01-13 2006-07-27 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Decladinosyl-macrolides with anti-inflammatory activity
JP5065910B2 (ja) 2005-01-14 2012-11-07 グラクソ グループ リミテッド ビオチンおよび光親和性基を含む、マクロライド標的同定用のマクロライド化合物
CN102378763A (zh) 2009-01-30 2012-03-14 葛兰素集团有限公司 消炎的大环内酯

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0895999A1 (en) * 1997-08-06 1999-02-10 Pfizer Products Inc. C-4" substituted macrolide antibiotics

Also Published As

Publication number Publication date
US8080529B2 (en) 2011-12-20
HK1112920A1 (en) 2008-09-19
KR20070105993A (ko) 2007-10-31
AU2006215315A1 (en) 2006-08-24
CA2594820A1 (en) 2006-08-24
IL184438A (en) 2011-12-29
CY1110866T1 (el) 2015-06-10
US20080221046A1 (en) 2008-09-11
JP2008526950A (ja) 2008-07-24
EP1851236A2 (en) 2007-11-07
EP1851236B1 (en) 2010-08-04
DK1851236T3 (da) 2010-11-22
AU2006215315B2 (en) 2012-02-16
PL1851236T3 (pl) 2011-05-31
ATE476438T1 (de) 2010-08-15
CN101142225A (zh) 2008-03-12
WO2006087644A3 (en) 2007-03-15
HRP20100549T1 (hr) 2010-11-30
JP5036558B2 (ja) 2012-09-26
DE602006015919D1 (de) 2010-09-16
WO2006087644A2 (en) 2006-08-24
NO20074162L (no) 2007-09-18
IL184438A0 (en) 2008-12-29
PT1851236E (pt) 2010-10-25
RS51479B (sr) 2011-04-30
US20120058963A1 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
US20120058963A1 (en) Macrolides with Anti-Inflammatory Activity
JP5118973B2 (ja) 新規ジヒドロシュードエリスロマイシン誘導体
WO2011131749A1 (en) New 14 and 15 membered macrolides for the treatment of neutrophil dominated inflammatory diseases
JP5437394B2 (ja) 抗炎症性マクロライド
JP5036557B2 (ja) 抗炎症活性デクラジノシル−マクロライド
CN101166749B (zh) 6-11桥联的肟乙基琥珀酸红霉素酯衍生物
JP2008532928A (ja) マクロライドとクマリンからなる抗炎症性複合体
JP2008519787A (ja) マクロロン化合物
JP2004529921A (ja) ロイコマイシンから誘導された９−アミノ−１４員環マクロライド
JP2011518799A (ja) ２’−ｏ，３’−ｎ−橋かけマクロライド
JP2012516305A (ja) 好中球優位の炎症性疾患の治療のための９−デオキソ−９ａ−メチル−９ａ−アザ−９ａ−ホモエリスロマイシンａ誘導体
JP2006528947A (ja) ４”−置換マクロライド
ES2349999T3 (es) Macrólidos con actividad anti-inflamatoria.
HK1112920B (en) Macrolides with anti-inflammatory activity
US20080200403A1 (en) 9A-Carbamoyl and Thiocarbamoyl Azalides with Anti-Inflammatory Activity
JP2016169178A (ja) 慢性鼻副鼻腔炎治療剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: GLAXO GROUP LIMITED

Free format text: FORMER OWNER: GLAXOSMITHKLINE ISTRAZIVACKI C.

Effective date: 20110422

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: ZAGREB, CROATIA TO: MIDDLESEX, THE UK

TA01 Transfer of patent application right

Effective date of registration: 20110422

Address after: British Meader Sykes

Applicant after: Glaxo Group Ltd.

Address before: Croatia Zagreb

Applicant before: Glaxosmithkline Istrazivacki C.

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110907

Termination date: 20140113